Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel

J Control Release. 2006 Mar 10;111(1-2):228-34. doi: 10.1016/j.jconrel.2005.12.013. Epub 2006 Feb 3.

Abstract

Self-assembled nanoparticles based on hydrophobically modified glycol chitosan (HGC) were prepared as a carrier for paclitaxel. HGC conjugates were prepared by chemically linking 5beta-cholanic acid to glycol chitosan chains using 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide chemistry. In phosphate-buffered saline (PBS; pH 7.4), the synthesized HGC conjugates formed nano-sized particles with a diameter of 200 nm and exhibited high thermodynamic stability as reflected by their low critical aggregation concentration (0.03 mg/ml). Paclitaxel was efficiently loaded into HGC nanoparticles up to 10 wt.% using a dialysis method. The paclitaxel-loaded HGC (PTX-HGC) nanoparticles were 400 nm in diameter and were stable in PBS for 10 days. These PTX-HGC nanoparticles also showed sustained release of the incorporated of paclitaxel (80% of the loaded dose was released in 8 days at 37 degrees C in PBS). Owing to sustained release, the PTX-HGC nanoparticles were less cytotoxic to B16F10 melanoma cells than free paclitaxel formulated in Cremophor EL. Injection of PTX-HGC nanoparticles into the tail vein of tumor-bearing mice prevented increases in tumor volume for 8 days. Finally, PTX was less toxic to the tumor-bearing mice when formulated in HGC nanoparticles than when formulated with Cremophor EL.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents, Phytogenic / administration & dosage
  • Antineoplastic Agents, Phytogenic / chemistry
  • Antineoplastic Agents, Phytogenic / pharmacology
  • Body Weight / drug effects
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Chitosan / chemistry*
  • Drug Carriers / chemistry
  • Glycerol / analogs & derivatives
  • Glycerol / chemistry
  • Humans
  • Hydrophobic and Hydrophilic Interactions*
  • Injections, Intravenous
  • Male
  • Melanoma, Experimental / drug therapy
  • Melanoma, Experimental / pathology
  • Mice
  • Mice, Inbred C57BL
  • Nanostructures / chemistry*
  • Paclitaxel / administration & dosage
  • Paclitaxel / chemistry
  • Paclitaxel / pharmacology*
  • Technology, Pharmaceutical / methods
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Phytogenic
  • Drug Carriers
  • glycol-chitosan
  • cremophor EL
  • Chitosan
  • Paclitaxel
  • Glycerol